PMA device
Epi proColon
New Day Diagnostics, LLC · System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection (PHP, Class III) · First FDA decision Apr 12, 2016, newest Nov 18, 2016Colorectal cancer and polyps
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
2
Naming "Epi proColon"
MAUDE reports
0
Brand "Epi proColon", since 2015
PubMed studies
45
Mentioning "Epi proColon"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Epi proColon
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- Epi proColonPMA supplement
P130001-S001 · Decided Nov 18, 2016 · 203 days after receipt · Normal 180 Day Track No User Fee
Device type: System, colorectal neoplasia, DNA methylation and hemoglobin detection (PHP) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39276CGS Administrators, LLCUpdated Feb 13, 2026
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39262Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39256Palmetto GBAUpdated Mar 4, 2025
- MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaLocal determinationIn effectL39356WPS Insurance CorporationUpdated Feb 20, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Epi proColon", any status and sponsor, newest update first.
- Longitudinal Performance of Epi proColonStatus unknown
Epigenomics, IncNot on our public-company list
NCT03218423 · 4,500 participants (planned) · Start Aug 18, 2017 · Primary completion Aug 2023
Device: Epi proColon · For: Colorectal Cancer; Colorectal Neoplasms
Sites: San Diego, California; Royal Oak, Michigan; New Brunswick, New Jersey · 6 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Epi proColon", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PHP
33 reports: 20 malfunction, 10 injury, 1 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1077-2018 · Started Nov 2, 2017
Reason given: The diagnostic test kit may produce invalid test runs which may delay test results.
Cause as FDA categorized it: Unknown/Undetermined by firm · Device type: System, Colorectal Neoplasia, Dna Methylation And Hemoglobin Detection (PHP)
Published research
The most relevant PubMed records for "Epi proColon"[tiab]. The summary above synthesizes these.
- Epi proColon® for Colorectal Cancer Screening: A Profile of Its Use in the USA.
Shirley M · Mol Diagn Ther · 2020Clinical Trial
- Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer.
Lamb YN, Dhillon S · Mol Diagn Ther · 2017
- mSEPT9 (Epi proColon) Blood Test for Colorectal Cancer Screening.
Lin KW · Am Fam Physician · 2019Review
- Non-Invasive Colorectal Cancer Screening: An Overview.
Tepus M, Yau TO · Gastrointest Tumors · 2020Review
- Gastrointestinal Conditions: Colorectal Cancer Screening and Prevention.
Davis J, Kellerman R · FP Essent · 2022
- BCAT1, IKZF1 and SEPT9: methylated DNA biomarkers for detection of pan-gastrointestinal adenocarcinomas.
Laven-Law G, Kichenadasse G, Young GP, et al. · Biomarkers · 2024
- Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis.
Hu J, Hu B, Gui YC, et al. · Med Sci Monit · 2019Meta-Analysis, Systematic Review
- Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study.
Johnson DA, Barclay RL, Mergener K, et al. · PLoS One · 2014Multicenter Study, Research Support, Non-U.S. Gov't
- Non-invasive colorectal cancer screening methods: focusing on diagnostic genetic and epigenetic markers.
Behrouzian Fard G, Amirfakhrian R, Hosseini Bafghi M, et al. · Cancer Cell Int · 2025Review
- Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach.
Deibel A, Deng L, Cheng CY, et al. · Gastrointest Endosc · 2021
- Plasma methylated septin 9: a colorectal cancer screening marker.
Molnár B, Tóth K, Barták BK, et al. · Expert Rev Mol Diagn · 2015
- Diagnostic Accuracy of a Blood-Based Biomarker Panel for Colorectal Cancer Detection: A Pilot Study.
Caraballo EV, Centeno-Girona H, Torres-Velásquez BC, et al. · Cancers (Basel) · 2024
Other devices of this type
Also filed under product code PHP.
- CologuardExact Sciences Corporation · PMA 2024
- ShieldGuardant Health, Inc. · PMA 2026
- SimpleScreen CRCFreenome, LLC · PMA 2026
- ColoHealthNew Day Diagnostics, LLC · PMA 2025
- Multi-Target Stool DNA (mtsDNA) Test, Cologuard PlusExact Sciences Corporation · PMA 2024
- Cologuard Stool DNA-Based Colorectal Cancer Screening TestExact Sciences Corporation · PMA 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.